Omega Diagnostics Group PLC announced that it has signed heads of terms with regards to a partnership agreement with a leading nutrigenomics software provider to develop and commercialise a bespoke DNA report for Omega. The report will be a unique and proprietary software tool which will expand the Company's product portfolio in line with its stated strategy to broaden its menu of tests. By understanding the relationship between nutrients, diet, and gene expression, nutrigenomics allows healthcare professionals to understand genetic strengths and weaknesses, making specific recommendations that help achieve better health outcomes for patients.

The parties will collaborate with a view to improving the awareness and understanding in the market of nutrigenomic testing, including the publication of educational materials and scientific studies. The report, which is intended to be utilised by healthcare professionals and their patients, will be designed to meet Omega's specific requirements while incorporating the current data and structure of the software provider's existing reports. This Agreement follows on from the microbiome testing partnership which was announced on 26 October 2022 and, once completed, will conclude the Company's initial product range expansion as previously set out in the Company's strategic plan.